Muscarinic-agonist antipsychotic (xanomeline-trospium)

1. Introduction

Version followed: US FDA Prescribing Information for COBENFY (xanomeline and trospium chloride) capsules, label revised 1/2026 (as reproduced on Drugs.com, checked October 2026), together with the FDA approval announcement of September 2024. Where other countries' status differs, it is stated separately below.

What it is. Xanomeline-trospium (brand name Cobenfy, developed as KarXT, marketed by Bristol Myers Squibb) is a prescription antipsychotic taken as oral capsules. The FDA approved it on 26 September 2024 for the treatment of schizophrenia in adults, describing it as the first antipsychotic for schizophrenia that "targets cholinergic receptors as opposed to dopamine receptors" [source: FDA press release 2024]. It combines two substances: xanomeline, a muscarinic receptor agonist that acts on the brain's cholinergic system, and trospium chloride, a muscarinic antagonist that is included to counter xanomeline's cholinergic side effects in the body [source: FDA 2024; Rethink Mental Illness]. Because it does not block dopamine D2 receptors, a published commentary argues it avoids the movement disorders, prolactin elevation, sedation, weight gain and metabolic effects typical of D2 antipsychotics, with cholinergic gastrointestinal effects as the trade-off; these are mechanistic, qualitative comparisons, not head-to-head data [source: Citrome 2025].

How change happens (as sources describe it). Symptom change comes from the medicine's effect on muscarinic signalling, which in turn modulates the dopamine-related circuits implicated in psychosis; in the two 5-week registration trials it reduced total PANSS scores compared with placebo in adults with acute schizophrenia [source: FDA 2024]. Claims about improvement in negative and cognitive symptoms appear in patient-facing and press sources, but the charity Rethink Mental Illness notes that some cognitive findings need further research [source: Rethink Mental Illness] [uncertain].

Who delivers it, and regulatory status. It is a prescription-only medicine chosen, started, monitored, changed and stopped only by a licensed prescriber (in practice usually a psychiatrist or psychiatric prescriber) [synthesis]. Status as found:

United States: FDA-approved (NDA 216158) for schizophrenia in adults; safety and effectiveness in children and adolescents are not established; the controlled trials did not include people over 65 [source: Drugs.com label].
Not an approved use: As an add-on to other antipsychotics, the phase 3 ARISE trial (adults with inadequately controlled schizophrenia already on an atypical antipsychotic) missed its primary endpoint, reported April 2025 [source: Fierce Pharma 2025]. Psychosis in Alzheimer's disease is under investigation in the ADEPT trials; BMS delayed the ADEPT-2 readout after site "irregularities" and expected results by the end of 2026, per a December 2025 report [source: BioSpace 2025]. Neither use is approved.
United Kingdom: An undated Rethink Mental Illness page said it was not yet licensed in England and would need MHRA and NICE approval before wide NHS use; a September 2025 trade report said BMS planned a UK launch in 2026 [source: Rethink Mental Illness; The Pharma Letter 2025]. Whether an MHRA licence or a NICE appraisal exists as of October 2026 is not confirmed [uncertain].
European Union: No EMA authorisation was found in searches made in October 2026 [uncertain].

Scope of this guide. The psychotherapist does not prescribe or adjust this medicine. This guide covers what the official label says, so the therapist can talk about it accurately, and what the therapist does alongside the prescriber. For dopamine-blocking antipsychotics, clozapine, depot injections, neuroleptic malignant syndrome, metabolic monitoring and general antipsychotic adherence work, see tab 002 Antipsychotics; this tab only covers what is specific to xanomeline-trospium.

2. Framework

This is a medicine, not a psychotherapy, so there are no therapy phases or session counts. The framework below is the therapist's work organised around the treatment course; the medical milestones come from the label, the organisation is [synthesis].

Phase A: Considering the medicine (before any prescription).

Goal: the client reaches an informed, shared decision with the prescriber. NICE's psychosis guideline says the choice of antipsychotic should be made jointly by the service user and clinician, considering carers' views if the service user agrees, after the clinician explains likely benefits and side effects [source: NICE CG178]. (NICE CG178 predates this medicine and does not mention it.)
Therapist tasks: psychoeducation from the label, help with preparing questions, explore hopes and fears, help gather a full medical and medication history for the prescriber (the label's contraindications are mainly bladder, liver, stomach and eye conditions) [source: Drugs.com label].
Moves on when: the prescriber and client decide, with consent documented by the prescriber.

Phase B: Starting (first weeks).

Medical side: the label asks prescribers to check liver enzymes and bilirubin before starting and heart rate at baseline, then as clinically indicated [source: Drugs.com label]. Cholinergic effects (nausea, vomiting, constipation) "generally began within 2 weeks of starting" in trials and were mostly mild to moderate and transient [source: Citrome 2025].
Therapist tasks: brief side-effect and warning-sign check at each session, ambivalence work when early nausea makes stopping tempting, passing on reports to the prescriber, keeping the crisis plan current.
Moves on when: the prescriber judges the starting period complete [synthesis].

Phase C: Continuation.

Therapist tasks: integrate psychological treatment (NICE recommends offering CBT for psychosis to all people with psychosis or schizophrenia, and family intervention to families in close contact [source: NICE CG178]), continue lower-frequency monitoring, relapse-signature work.

Phase D: Change or ending (prescriber-led).

If the prescriber and client decide on a change or ending, the therapist supports the client through it, watches for early relapse signs and side effects, and keeps communication open with the prescriber. The therapist does not suggest or plan the change [synthesis].

Format. Medication is reviewed in prescriber appointments; the therapist's work happens in ordinary individual, family or group sessions, with a short structured medication check-in (a few minutes) built in [synthesis].

3. Guiding principles

The prescriber owns every medication decision. Questions about whether to start, take, change or stop go to the prescriber, every time [source: Rethink Mental Illness advises not stopping "without getting advice first"].
Label-based accuracy. Describe benefits, warnings and side effects as the official label states them, and say which country's label you mean; status differs between countries [source: Drugs.com label].
Different medicine, different watch list. The safety concerns here (urinary retention, liver and gallbladder effects, slowed stomach emptying, facial or throat swelling, narrow-angle glaucoma, fast heart rate, confusion) are not the usual antipsychotic list, so adapt your check-ins [source: Drugs.com label].
No assumptions from absent warnings. The US label lacks the class warnings for D2 antipsychotics, including the boxed warning about older people with dementia-related psychosis [source: Citrome 2025], but this population was not studied and the medicine is not approved for it; absence of a warning is not evidence of safety [synthesis].
Neither salesperson nor sceptic. Media coverage called it a breakthrough; the add-on trial failed and other uses are unproven. Give balanced information and let the prescriber advise [source: Fierce Pharma 2025] [synthesis].
Shared decision-making and autonomy. Support the client to state their own priorities (side effects they most want to avoid, goals) in prescriber discussions [source: NICE CG178].
Collaborative care with consent. Agree in writing what you may share with the prescriber and when you will contact them without asking first (emergencies) [synthesis].
Ambivalence is explored, not resolved by you. Curiosity about doubts, never persuasion either way [synthesis].
Psychotherapy continues alongside. Medication does not replace CBT for psychosis or family intervention [source: NICE CG178].
Stay within competence. Do not interpret lab results, symptoms or interactions; pass observations on [synthesis].

4. Intervention inventory

Part A describes the treatment as the official US label publishes it, at a descriptive level, so the therapist can recognise what clients are told and what to pass on. Part B is the therapist's own work. No dosing, titration or scheduling information is given here; the prescriber and pharmacist provide it.

A1. How the treatment is delivered (official labelling, descriptive)

Purpose: Accurate background for psychoeducation and side-effect monitoring.
What the label describes: An oral capsule (coated pellets inside a capsule), prescribed for adults with schizophrenia, supplied in bottles, hospital blister packs and a starter pack. The label has specific instructions on how to take the capsules, including timing relative to meals and not opening the capsules; the prescriber and pharmacist explain these. Patients are told to take it as directed and not to change the dose or stop without talking to their provider [source: Drugs.com label]. A commentary notes that gastrointestinal effects may be worse if the instructions about meals are not followed [source: Citrome 2025].
Checks the label asks prescribers to make: liver enzymes and bilirubin before starting and as clinically indicated; heart rate at baseline and as indicated; watching for anticholinergic effects on thinking (dizziness, confusion, hallucinations, sleepiness), especially after starting or after a prescriber changes the dose [source: Drugs.com label].
Boxed warning: None on the US label [source: Drugs.com label]. It also lacks the D2-antipsychotic class warnings, including the one about older people with dementia-related psychosis [source: Citrome 2025].
Watch for: Clients assuming that "no boxed warning" means "no risks"; correct gently using the warnings list below [synthesis].

A2. Contraindications (who should not take it, per label)

Purpose: Help the client tell the prescriber about relevant history.
Content: The US label lists urinary retention; moderate or severe liver impairment; gastric retention; previous hypersensitivity to the product or to trospium; and untreated narrow-angle glaucoma [source: Drugs.com label]. The label also says it is not recommended in mild liver impairment, in active biliary disease such as symptomatic gallstones, or in moderate or severe kidney impairment [source: Drugs.com label; FDA 2024].
Therapist use: If a client mentions bladder problems, prostate enlargement, liver or gallbladder disease, kidney disease, glaucoma or eye-pressure problems, bowel conditions such as ulcerative colitis, or myasthenia gravis, encourage them to make sure the prescriber knows [source: Drugs.com label, sections 5.1 to 5.8 and 17].

A3. Warnings and precautions (US label sections 5.1 to 5.9)

Summarised in plain words from the label [source: Drugs.com label]:

Urinary retention: Higher risk in older people and those with bladder outlet obstruction (for example enlarged prostate) or incomplete emptying. Signs: hesitancy, weak stream, feeling of incomplete emptying, painful urination. Inability to urinate needs immediate medical care.
Liver impairment: Signs to report: yellow skin or eyes, dark urine, abdominal pain or swelling, itching.
Biliary disease: Temporary liver-enzyme rises consistent with bile-duct obstruction have occurred. Indigestion, nausea, vomiting or upper abdominal pain should prompt medical evaluation of the gallbladder, bile ducts or pancreas.
Slowed stomach and gut movement: Caution in gut obstruction, ulcerative colitis, intestinal atony and myasthenia gravis.
Angioedema: Swelling of the face, lips, tongue or throat has been reported and can be life-threatening. Patients are told to stop and seek immediate care for swelling of the tongue, throat or face or difficulty breathing (this is a label instruction for an emergency, not therapist advice).
Narrow-angle glaucoma: Pupil dilation can trigger an attack. Signs: red eyes, blurred vision, halos around lights, eye pain, severe headache.
Increased heart rate: Report a racing or pounding heartbeat.
Kidney impairment: Anticholinergic effects (dry mouth, constipation, indigestion, urinary infection, urinary retention) are expected to be greater.
Effects on thinking: Dizziness, confusion, hallucinations and sleepiness have been associated with trospium. Patients are advised not to drive or operate heavy machinery until they know how it affects them.

A4. Common side effects and course

Label: Most common (at least 5% and at least twice placebo): nausea, indigestion, constipation, vomiting, high blood pressure, abdominal pain, diarrhoea, fast heart rate, dizziness and reflux. Also reported: dry mouth, sleepiness, blurred vision, excess saliva, dizziness on standing and extrapyramidal symptoms. In the 5-week trials 6% stopped because of side effects versus 4% on placebo [source: Drugs.com label].
Course: Cholinergic effects generally began within the first two weeks and were mostly mild to moderate and transient; long-term data were available only as conference posters at the time [source: Citrome 2025].
Watch for: Early nausea or vomiting driving a wish to stop; constipation going unreported because of embarrassment [synthesis].

A5. Interactions, special populations and overdose (descriptive)

Interaction categories on the label: strong CYP2D6 inhibitors; drugs removed by active tubular secretion in the kidney; sensitive CYP3A4 substrates; P-glycoprotein substrates; other antimuscarinic (anticholinergic) drugs, with additive effects; and altered absorption of other drugs because of slowed gut movement [source: Drugs.com label]. Therapist role: encourage the client to give every prescriber and pharmacist a complete list, including over-the-counter and herbal products. Do not judge whether a combination is safe [synthesis].
Pregnancy and breastfeeding: No adequate human data; untreated schizophrenia carries its own risks; a pregnancy exposure registry exists; it is unknown whether it passes into breast milk [source: Drugs.com label]. Therapist role: encourage the client to tell the prescriber promptly if pregnant, planning pregnancy or breastfeeding.
Older adults: Not included in the controlled trials; higher urinary-retention risk; the label gives the prescriber separate guidance for this group [source: Drugs.com label].
Children and adolescents: Safety and effectiveness not established [source: Drugs.com label].
Overdose signs described on the label: cholinergic signs (seizures, vomiting, diarrhoea, abdominal pain, sweating, excess saliva, low blood pressure) or anticholinergic signs (delirium, agitation, garbled speech, fast heart rate, dry mouth and eyes, blurred vision, urinary retention); the US label points to the Poison Help Line (1-800-222-1222) [source: Drugs.com label]. Any suspected overdose is an emergency: call emergency services or poison control [synthesis].

B1. Recognising when to suggest a medical review

Purpose: Get the client to the prescriber when something needs medical judgement. The triggers come from the label; the routing is [synthesis].
Steps:
1. Same day, by emergency services: inability to urinate; swelling of the face, lips, tongue or throat or difficulty breathing; suspected overdose; severe eye pain with vision changes and headache [source: Drugs.com label].
2. Promptly (same or next working day): yellow skin or eyes, dark urine, abdominal pain or swelling, itching; persistent upper abdominal pain with nausea or vomiting; racing or pounding heartbeat; new confusion, hallucinations of a different quality, or marked drowsiness; difficulty passing urine; worsening constipation [source: Drugs.com label].
3. At the next prescriber contact: troublesome nausea, indigestion, dry mouth, dizziness; questions about pregnancy, breastfeeding or new medicines; any wish to stop or change [synthesis].
4. Return of psychotic symptoms, a new suicide or violence risk, or a crisis: follow the crisis plan (B8) and standard risk procedures [synthesis].
Example language (illustrative): "That trouble passing urine is on the list the leaflet says to get checked straight away. Can we call your prescriber's team now, together?"
Watch for: Distinguishing relapse from a side effect is a medical task; new confusion or hallucinations may be either, so pass it on without interpreting [source: Drugs.com label section 5.9] [synthesis].

B2. Referral and collaborative care

Purpose: Connect the client to a prescriber when medication has not been discussed, and keep therapist and prescriber working as one team.
Steps:
1. If a client with psychosis or schizophrenia has no prescriber, or raises interest in this medicine, refer to a psychiatrist or the community mental health team rather than discussing suitability yourself [synthesis].
2. Get written consent for two-way information sharing: what, with whom (prescriber, GP or primary care doctor, pharmacist, family), how often, and when you will contact the prescriber without asking first (emergencies) [synthesis].
3. Agree one contact route and a response timeframe with the prescriber's team [synthesis].
4. Send brief, factual updates: observations, client's own words, dates; no recommendations about the medicine [synthesis].
Example language (illustrative), to a prescriber: "Since starting, Ms A reports daily nausea and says she is thinking of stopping. She has agreed I share this. She would like to discuss it at her review."
Watch for / working: The prescriber learns about side effects before the client stops on their own [synthesis].

B3. Psychoeducation

Purpose: Give accurate, balanced information so the client can take part in decisions.
Steps:
1. Ask what the client has already heard (media, peers, online) [synthesis].
2. Explain in plain words: a different type of antipsychotic that works on the cholinergic (acetylcholine) system instead of blocking dopamine; two ingredients, one acting on the brain and one included to reduce side effects in the body [source: FDA 2024; Rethink Mental Illness].
3. Give the label's approved use (adults with schizophrenia, US) and what it is not approved for (add-on use, dementia psychosis, children) [source: Drugs.com label; Fierce Pharma 2025; BioSpace 2025].
4. Describe the side-effect profile honestly: early stomach and bowel effects are common and often settle; the label's serious warnings are listed in A3 [source: Drugs.com label; Citrome 2025].
5. Point to official materials: the Medication Guide from the pharmacy, the prescriber and pharmacist for questions [synthesis].
Example language (illustrative): "This works on a different brain chemical from your previous medicines. People tend to get stomach upset early on rather than weight gain or stiffness, but it has its own warnings. Your prescriber can tell you whether it suits you."
Watch for: Overselling ("no side effects") or underselling; clients with paranoid beliefs about a "new experimental drug" may need extra time [synthesis].

B4. Supporting informed consent and shared decision-making

Purpose: Help the client bring their own priorities to the prescriber [source: NICE CG178 on shared decisions and explaining benefits and side effects].
Steps:
1. Ask what matters most: symptoms to target, side effects to avoid (for example weight gain, stiffness, sleepiness, nausea), practical issues (cost, insurance or availability) [synthesis].
2. Help prepare a list of questions, for example: Is it suitable for my health history? What checks will I need? What side effects should I report and how? What happens if it does not help? [synthesis]
3. Help gather history the prescriber will need (A2) and a full medicine list (A5) [source: Drugs.com label].
4. With consent, involve a carer in preparation if the client wants that [source: NICE CG178].
5. Afterwards, check understanding: what was decided, and what the client will watch for [synthesis].
Example language (illustrative): "Shall we write down the three questions you most want answered before your appointment?"
Watch for: Capacity concerns during acute psychosis: raise them with the prescriber, who assesses capacity for treatment decisions [synthesis].

B5. Adherence and ambivalence conversations

Purpose: Explore doubts openly so they reach the prescriber; never advise taking, stopping or changing.
Steps:
1. Ask neutrally how the client is taking it in practice, without judgement [synthesis].
2. Explore both sides of the ambivalence (what they get from it, what it costs them), reflecting in their words (motivational-interviewing-style listening) [synthesis].
3. Name the specific side effect behind a wish to stop (often early nausea or constipation) and link it to the prescriber, who has management options [source: Citrome 2025 on early, often transient GI effects] [synthesis].
4. Make clear that decisions about change go through the prescriber, as Rethink Mental Illness advises [source: Rethink Mental Illness].
5. If the client has already stopped or changed, avoid blame; encourage telling the prescriber soon; increase relapse-sign monitoring (B8) [synthesis].
Example language (illustrative): "Part of you wants to give it a fair try, and part of you is fed up with feeling sick. Both make sense. What would you want your prescriber to know about this?"
Watch for: Your own views about medicine steering the conversation; a client reading neutrality as permission to stop [synthesis].

B6. Monitoring side effects and passing them on

Purpose: Catch label-listed problems early and report them.
Steps:
1. In the starting period, ask briefly at each session about: nausea, vomiting, indigestion, reflux; constipation or diarrhoea; difficulty passing urine; abdominal pain; racing heartbeat; dizziness, confusion or drowsiness; eye pain or vision changes; any swelling [source: Drugs.com label].
2. Use the client's own words; note dates and severity [synthesis].
3. Route by urgency (B1) [synthesis].
4. Reduce frequency once stable, as agreed with the prescriber [synthesis].
5. Remind the client of the label's advice about driving and machinery until they know how it affects them [source: Drugs.com label].
Example language (illustrative): "Quick check on the medicine: any stomach or bowel trouble, problems passing water, racing heart or feeling muddled this week?"
Watch for: Constipation and urinary symptoms often go unreported; ask directly. Working: the prescriber hears about issues within days, not at the next routine review [synthesis].

B7. Responding to an emergency warning sign in session

Purpose: Act quickly on the label's emergencies.
Steps:
1. Swelling of the tongue, throat or face, or difficulty breathing: call emergency services; the label tells patients to stop the medicine and seek immediate care [source: Drugs.com label].
2. Cannot urinate: same-day emergency care [source: Drugs.com label].
3. Severe eye pain, red eye, blurred vision with halos, severe headache: urgent same-day medical care [source: Drugs.com label] [synthesis on route].
4. Suspected overdose: emergency services or poison control [source: Drugs.com label].
5. Tell the prescriber's team as soon as safe; document [synthesis].
Example language (illustrative): "This swelling needs urgent medical help. I'm calling for an ambulance now, and I'll stay with you."
Watch for: Therapist hesitating to "overreact"; these signs warrant emergency care [synthesis].

B8. Crisis and safety planning

Purpose: Keep a written plan for psychotic relapse, suicide risk and medication emergencies [synthesis].
Steps:
1. Map the client's personal relapse signature (early signs, triggers) with them and, with consent, their family [synthesis].
2. Add a medication section: the label's emergency signs (B7), prescriber and pharmacy contacts, out-of-hours numbers [source: Drugs.com label] [synthesis].
3. Follow current standard suicide risk assessment and safety planning, including lethal-means counselling (safe storage of medicines) [synthesis].
4. Update the plan at each medication change made by the prescriber, and after any crisis [synthesis].
Example language (illustrative): "Let's add to your plan what you'd do if the medicine caused a problem, and who you'd call at night."
Watch for: Plans that cover relapse but not physical warning signs, or the reverse [synthesis].

B9. Integrating psychotherapy before, during and after

Purpose: Medication is one part of care; NICE recommends offering CBT to all people with psychosis or schizophrenia, family intervention to families in close contact, and assessing for trauma [source: NICE CG178].
Steps:
1. Before and during: continue CBT for psychosis or other indicated therapy; do not pause therapy because medication is starting [source: NICE CG178] [synthesis].
2. During early weeks: adjust session timing or length if nausea or dizziness interferes; keep sessions brief and practical if needed [synthesis].
3. Use therapy to work on goals medication alone may not address (functioning, relationships, meaning, residual symptoms); do not promise cognitive or negative-symptom benefits, which are not established [source: Rethink Mental Illness] [synthesis].
4. Offer family intervention with consent [source: NICE CG178].
5. Assess for PTSD and trauma reactions and follow the PTSD guideline where indicated [source: NICE CG178].
Watch for / working: Therapy goals progressing independent of medication decisions [synthesis].
Example language (illustrative): "Starting a new medicine doesn't put our work on hold. If the nausea makes a full session hard, we can keep sessions shorter for a while and pick up the full plan when you're ready." [synthesis]

B10. Support through changes and after treatment ends

Purpose: Support the client when the prescriber and client decide to change or end this medicine, including when it did not help or was not tolerated.
Steps:
1. Help the client prepare questions for the prescriber about what to expect during any change [synthesis].
2. Increase relapse-signature and side-effect check-ins during and after the change; pass on observations [synthesis].
3. Work with disappointment if a hoped-for "new" medicine did not work; normalise trial and adjustment [synthesis].
4. For general switching issues between antipsychotics, see tab 002 Antipsychotics [synthesis].
Example language (illustrative): "You had high hopes for this one. How are you making sense of it not suiting you?"
Watch for: Hopelessness after a failed trial; renewed suicide risk assessment as needed [synthesis].

5. Handling problems

The sources cover medical warnings, not therapist difficulties, so the responses below are [synthesis] unless a source is tagged.

"I feel sick all the time, I'm stopping." Acknowledge the distress; explain that the label lists stomach effects as common and a commentary reports they usually start early and are often temporary [source: Citrome 2025]; say the prescriber has options to discuss; offer to contact the prescriber with the client today. Do not suggest they keep taking it or stop.
Client asks, "Should I switch to Cobenfy? I don't want to gain more weight." Validate the concern; give balanced information (B3); say suitability and switching are the prescriber's decision; help prepare questions (B4). See tab 002 for general switching issues.
Media hype or a breakthrough expectation. Give the approved use and the failed add-on trial result [source: Fierce Pharma 2025]; explore what the client hopes will change and what therapy can work on meanwhile.
Client wants it but cannot get it (cost, insurance, not available in their country). Explore the frustration; signpost the prescriber, pharmacist or social worker for access questions; note it was not confirmed as licensed in the UK or EU in sources checked [uncertain].
Paranoid beliefs about the medicine ("they're testing a new drug on me"). Avoid arguing; work with the belief using CBT for psychosis methods; involve the prescriber, who explains the treatment and its approval status; respect the client's right to decline.
Non-adherence discovered. No blame; explore reasons (B5); encourage telling the prescriber; tighten relapse monitoring; update the crisis plan.
New confusion, odd perceptions or drowsiness. Do not decide whether it is relapse or a side effect; the label lists confusion, hallucinations and sleepiness as possible anticholinergic effects [source: Drugs.com label]; pass on promptly; check safety and driving.
Several medicines with anticholinergic effects. Do not assess the combination; ask the client to make sure the prescriber and pharmacist have a full list, since the label flags additive effects with other antimuscarinic drugs [source: Drugs.com label].
Embarrassing symptoms not reported (constipation, urinary problems). Ask directly and matter-of-factly; normalise; explain why they matter (B6).
Older client, or a relative with dementia, being offered it. Note that the controlled trials excluded people over 65 and that dementia-related psychosis is not an approved use [source: Drugs.com label; BioSpace 2025]; encourage questions to the prescriber; avoid giving a view on suitability.
Pregnancy or breastfeeding. Encourage prompt contact with the prescriber; mention that a pregnancy registry exists [source: Drugs.com label]; do not advise stopping.
Prescriber unreachable when a problem arises. Use the agreed out-of-hours route, primary care or pharmacist for non-urgent issues, and emergency services for B7 signs; document.
Rupture: client feels the therapist is "pushing pills" or "against medication". Name and repair it; restate your role (you support their decisions with the prescriber, and pass on concerns); ask what they need from you.
Family pressure to take or stop. With consent, offer a family session focused on information and the client's own priorities; NICE supports carer involvement where the service user agrees [source: NICE CG178].
Therapist uncertainty about medical facts. Say you do not know and find out from the label or the prescriber; do not guess.
Stuck therapy because the client waits for the medicine to fix everything. Agree goals that do not depend on medication; review progress on them separately.

Sources

Sources:

Not confirmed: MHRA licence and NICE appraisal status as of October 2026; EMA status [uncertain].

← Previous · IX-002Antipsychotics, clozapine and long-acting injectables Next · IX-004 →Mood stabilisers including lithium